lilly tirzepatide weight loss orforglipron oral GLP-1 phase 3 trial Eli Lilly targets FDA approval

However, they should be prescribed based on individual health status and weight loss progress

However, everyones body reacts differently, so its possible some individuals might not see the same results

On December 15, 2025, the United States Judicial Panel on Multidistrict Litigation (JPML) announced a new multidistrict litigation (MDL) docket

Based on these results, the company plans to launch a new phase 3 Programme called RENEW later this year

This may lead to straining during defecation, which increases intra-abdominal and venous pressure in the hemorrhoidal plexus

Injectable medications require special care, she says